Tempus AI (NASDAQ:TEM – Get Free Report) and biote (NASDAQ:BTMD – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership.
Analyst Recommendations
This is a summary of current recommendations and price targets for Tempus AI and biote, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Tempus AI | 1 | 10 | 11 | 0 | 2.45 |
| biote | 1 | 1 | 1 | 1 | 2.50 |
Tempus AI currently has a consensus price target of $79.37, indicating a potential upside of 14.46%. biote has a consensus price target of $2.50, indicating a potential upside of 134.74%. Given biote’s stronger consensus rating and higher probable upside, analysts clearly believe biote is more favorable than Tempus AI.
Volatility and Risk
Tempus AI has a beta of 3.61, suggesting that its share price is 261% more volatile than the S&P 500. Comparatively, biote has a beta of 1.73, suggesting that its share price is 73% more volatile than the S&P 500.
Earnings & Valuation
This table compares Tempus AI and biote”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Tempus AI | $1.27 billion | 9.95 | -$245.03 million | ($1.06) | -65.42 |
| biote | $192.22 million | 0.20 | $27.05 million | ($0.10) | -10.65 |
biote has lower revenue, but higher earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Tempus AI and biote’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Tempus AI | -12.54% | -47.00% | -9.44% |
| biote | -1.08% | -8.61% | 4.61% |
Insider and Institutional Ownership
24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 21.7% of biote shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by company insiders. Comparatively, 32.4% of biote shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Summary
biote beats Tempus AI on 10 of the 15 factors compared between the two stocks.
About Tempus AI
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
About biote
Biote Inc. (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services. The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
